Cargando…

Lower plasma PCSK9 in normocholesterolemic subjects is associated with upregulated adipose tissue surface‐expression of LDLR and CD36 and NLRP3 inflammasome

BACKGROUND: LDL‐cholesterol lowering variants that upregulate receptor uptake of LDL, such as in PCSK9 and HMGCR, are associated with diabetes via unclear mechanisms. Activation of the NLRP3 inflammasome/interleukin‐1 beta (IL‐1β) pathway promotes white adipose tissue (WAT) dysfunction and type 2 di...

Descripción completa

Detalles Bibliográficos
Autores principales: Cyr, Yannick, Lamantia, Valérie, Bissonnette, Simon, Burnette, Melanie, Besse‐Patin, Aurèle, Demers, Annie, Wabitsch, Martin, Chrétien, Michel, Mayer, Gaétan, Estall, Jennifer L., Saleh, Maya, Faraj, May
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7851436/
https://www.ncbi.nlm.nih.gov/pubmed/33527668
http://dx.doi.org/10.14814/phy2.14721
_version_ 1783645628449947648
author Cyr, Yannick
Lamantia, Valérie
Bissonnette, Simon
Burnette, Melanie
Besse‐Patin, Aurèle
Demers, Annie
Wabitsch, Martin
Chrétien, Michel
Mayer, Gaétan
Estall, Jennifer L.
Saleh, Maya
Faraj, May
author_facet Cyr, Yannick
Lamantia, Valérie
Bissonnette, Simon
Burnette, Melanie
Besse‐Patin, Aurèle
Demers, Annie
Wabitsch, Martin
Chrétien, Michel
Mayer, Gaétan
Estall, Jennifer L.
Saleh, Maya
Faraj, May
author_sort Cyr, Yannick
collection PubMed
description BACKGROUND: LDL‐cholesterol lowering variants that upregulate receptor uptake of LDL, such as in PCSK9 and HMGCR, are associated with diabetes via unclear mechanisms. Activation of the NLRP3 inflammasome/interleukin‐1 beta (IL‐1β) pathway promotes white adipose tissue (WAT) dysfunction and type 2 diabetes (T2D) and is regulated by LDL receptors (LDLR and CD36). We hypothesized that: (a) normocholesterolemic subjects with lower plasma PCSK9, identifying those with higher WAT surface‐expression of LDLR and CD36, have higher activation of WAT NLRP3 inflammasome and T2D risk factors, and; (b) LDL upregulate adipocyte NLRP3 inflammasome and inhibit adipocyte function. METHODOLOGY: Post hoc analysis was conducted in 27 overweight/ obese subjects with normal plasma LDL‐C and measures of disposition index (DI during Botnia clamps) and postprandial fat metabolism. WAT was assessed for surface‐expression of LDLR and CD36 (immunohistochemistry), protein expression (immunoblot), IL‐1β secretion (AlphaLISA), and function ((3)H‐triolein storage). RESULTS: Compared to subjects with higher than median plasma PCSK9, subjects with lower PCSK9 had higher WAT surface‐expression of LDLR (+81%) and CD36 (+36%), WAT IL‐1β secretion (+284%), plasma IL‐1 receptor‐antagonist (+85%), and postprandial hypertriglyceridemia, and lower WAT pro‐IL‐1β protein (−66%), WAT function (−62%), and DI (−28%), without group‐differences in body composition, energy intake or expenditure. Adjusting for WAT LDLR or CD36 eliminated group‐differences in WAT function, DI, and postprandial hypertriglyceridemia. Native LDL inhibited Simpson‐Golabi Behmel‐syndrome (SGBS) adipocyte differentiation and function and increased inflammation. CONCLUSION: Normocholesterolemic subjects with lower plasma PCSK9 and higher WAT surface‐expression of LDLR and CD36 have higher WAT NLRP3 inflammasome activation and T2D risk factors. This may be due to LDL‐induced inhibition of adipocyte function.
format Online
Article
Text
id pubmed-7851436
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-78514362021-02-05 Lower plasma PCSK9 in normocholesterolemic subjects is associated with upregulated adipose tissue surface‐expression of LDLR and CD36 and NLRP3 inflammasome Cyr, Yannick Lamantia, Valérie Bissonnette, Simon Burnette, Melanie Besse‐Patin, Aurèle Demers, Annie Wabitsch, Martin Chrétien, Michel Mayer, Gaétan Estall, Jennifer L. Saleh, Maya Faraj, May Physiol Rep Original Research BACKGROUND: LDL‐cholesterol lowering variants that upregulate receptor uptake of LDL, such as in PCSK9 and HMGCR, are associated with diabetes via unclear mechanisms. Activation of the NLRP3 inflammasome/interleukin‐1 beta (IL‐1β) pathway promotes white adipose tissue (WAT) dysfunction and type 2 diabetes (T2D) and is regulated by LDL receptors (LDLR and CD36). We hypothesized that: (a) normocholesterolemic subjects with lower plasma PCSK9, identifying those with higher WAT surface‐expression of LDLR and CD36, have higher activation of WAT NLRP3 inflammasome and T2D risk factors, and; (b) LDL upregulate adipocyte NLRP3 inflammasome and inhibit adipocyte function. METHODOLOGY: Post hoc analysis was conducted in 27 overweight/ obese subjects with normal plasma LDL‐C and measures of disposition index (DI during Botnia clamps) and postprandial fat metabolism. WAT was assessed for surface‐expression of LDLR and CD36 (immunohistochemistry), protein expression (immunoblot), IL‐1β secretion (AlphaLISA), and function ((3)H‐triolein storage). RESULTS: Compared to subjects with higher than median plasma PCSK9, subjects with lower PCSK9 had higher WAT surface‐expression of LDLR (+81%) and CD36 (+36%), WAT IL‐1β secretion (+284%), plasma IL‐1 receptor‐antagonist (+85%), and postprandial hypertriglyceridemia, and lower WAT pro‐IL‐1β protein (−66%), WAT function (−62%), and DI (−28%), without group‐differences in body composition, energy intake or expenditure. Adjusting for WAT LDLR or CD36 eliminated group‐differences in WAT function, DI, and postprandial hypertriglyceridemia. Native LDL inhibited Simpson‐Golabi Behmel‐syndrome (SGBS) adipocyte differentiation and function and increased inflammation. CONCLUSION: Normocholesterolemic subjects with lower plasma PCSK9 and higher WAT surface‐expression of LDLR and CD36 have higher WAT NLRP3 inflammasome activation and T2D risk factors. This may be due to LDL‐induced inhibition of adipocyte function. John Wiley and Sons Inc. 2021-02-01 /pmc/articles/PMC7851436/ /pubmed/33527668 http://dx.doi.org/10.14814/phy2.14721 Text en © 2021 The Authors. Physiological Reports published by Wiley Periodicals LLC on behalf of The Physiological Society and the American Physiological Society This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Research
Cyr, Yannick
Lamantia, Valérie
Bissonnette, Simon
Burnette, Melanie
Besse‐Patin, Aurèle
Demers, Annie
Wabitsch, Martin
Chrétien, Michel
Mayer, Gaétan
Estall, Jennifer L.
Saleh, Maya
Faraj, May
Lower plasma PCSK9 in normocholesterolemic subjects is associated with upregulated adipose tissue surface‐expression of LDLR and CD36 and NLRP3 inflammasome
title Lower plasma PCSK9 in normocholesterolemic subjects is associated with upregulated adipose tissue surface‐expression of LDLR and CD36 and NLRP3 inflammasome
title_full Lower plasma PCSK9 in normocholesterolemic subjects is associated with upregulated adipose tissue surface‐expression of LDLR and CD36 and NLRP3 inflammasome
title_fullStr Lower plasma PCSK9 in normocholesterolemic subjects is associated with upregulated adipose tissue surface‐expression of LDLR and CD36 and NLRP3 inflammasome
title_full_unstemmed Lower plasma PCSK9 in normocholesterolemic subjects is associated with upregulated adipose tissue surface‐expression of LDLR and CD36 and NLRP3 inflammasome
title_short Lower plasma PCSK9 in normocholesterolemic subjects is associated with upregulated adipose tissue surface‐expression of LDLR and CD36 and NLRP3 inflammasome
title_sort lower plasma pcsk9 in normocholesterolemic subjects is associated with upregulated adipose tissue surface‐expression of ldlr and cd36 and nlrp3 inflammasome
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7851436/
https://www.ncbi.nlm.nih.gov/pubmed/33527668
http://dx.doi.org/10.14814/phy2.14721
work_keys_str_mv AT cyryannick lowerplasmapcsk9innormocholesterolemicsubjectsisassociatedwithupregulatedadiposetissuesurfaceexpressionofldlrandcd36andnlrp3inflammasome
AT lamantiavalerie lowerplasmapcsk9innormocholesterolemicsubjectsisassociatedwithupregulatedadiposetissuesurfaceexpressionofldlrandcd36andnlrp3inflammasome
AT bissonnettesimon lowerplasmapcsk9innormocholesterolemicsubjectsisassociatedwithupregulatedadiposetissuesurfaceexpressionofldlrandcd36andnlrp3inflammasome
AT burnettemelanie lowerplasmapcsk9innormocholesterolemicsubjectsisassociatedwithupregulatedadiposetissuesurfaceexpressionofldlrandcd36andnlrp3inflammasome
AT bessepatinaurele lowerplasmapcsk9innormocholesterolemicsubjectsisassociatedwithupregulatedadiposetissuesurfaceexpressionofldlrandcd36andnlrp3inflammasome
AT demersannie lowerplasmapcsk9innormocholesterolemicsubjectsisassociatedwithupregulatedadiposetissuesurfaceexpressionofldlrandcd36andnlrp3inflammasome
AT wabitschmartin lowerplasmapcsk9innormocholesterolemicsubjectsisassociatedwithupregulatedadiposetissuesurfaceexpressionofldlrandcd36andnlrp3inflammasome
AT chretienmichel lowerplasmapcsk9innormocholesterolemicsubjectsisassociatedwithupregulatedadiposetissuesurfaceexpressionofldlrandcd36andnlrp3inflammasome
AT mayergaetan lowerplasmapcsk9innormocholesterolemicsubjectsisassociatedwithupregulatedadiposetissuesurfaceexpressionofldlrandcd36andnlrp3inflammasome
AT estalljenniferl lowerplasmapcsk9innormocholesterolemicsubjectsisassociatedwithupregulatedadiposetissuesurfaceexpressionofldlrandcd36andnlrp3inflammasome
AT salehmaya lowerplasmapcsk9innormocholesterolemicsubjectsisassociatedwithupregulatedadiposetissuesurfaceexpressionofldlrandcd36andnlrp3inflammasome
AT farajmay lowerplasmapcsk9innormocholesterolemicsubjectsisassociatedwithupregulatedadiposetissuesurfaceexpressionofldlrandcd36andnlrp3inflammasome